Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.
Inactivation of phosphatase and tensin homolog (PTEN) is a critical step during tumorigenesis, and PTEN inactivation by genetic and epigenetic means has been well studied. There is also evidence suggesting that PTEN negative regulators (PTEN-NRs) have a role in PTEN inactivation during tumorigenesis, but their identity has remained elusive. Here we have identified shank-interacting protein-like 1 (SIPL1) as a PTEN-NR in human tumor cell lines and human primary cervical cancer cells. Ectopic SIPL1 expression protected human U87 glioma cells from PTEN-mediated growth inhibition and promoted the formation of HeLa cell-derived xenograft tumors in immunocompromised mice. Conversely, siRNA-mediated knockdown of SIPL1 expression inhibited the growth of both HeLa cells and DU145 human prostate carcinoma cells in vitro and in vivo in a xenograft tumor model. These inhibitions were reversed by concomitant knockdown of PTEN, demonstrating that SIPL1 affects tumorigenesis via inhibition of PTEN function. Mechanistically, SIPL1 was found to interact with PTEN through its ubiquitin-like domain (UBL), inhibiting the phosphatidylinositol 3,4,5-trisphosphate (PIP3) phosphatase activity of PTEN. Furthermore, SIPL1 expression correlated with loss of PTEN function in PTEN-positive human primary cervical cancer tissue. Taken together, these observations indicate that SIPL1 is a PTEN-NR and that it facilitates tumorigenesis, at least in part, through its PTEN inhibitory function.
He
Lizhi
L
Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Ingram
Alistair
A
Rybak
Adrian P
AP
Tang
Damu
D
D045744:Cell Line, Tumor; D002477:Cells / Q000378:metabolism / Q000473:pathology; D022082:Cellular Structures / Q000378:metabolism / Q000473:pathology; D005796:Genes; D006367:HeLa Cells; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism*; D051059:PTEN Phosphohydrolase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018129:Phosphatidylinositol Phosphates / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D010716:Phosphatidylinositols / Q000235:genetics / Q000378:metabolism; D010744:Phosphoric Monoester Hydrolases / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D011506:Proteins / Q000235:genetics / Q000378:metabolism
D018129:Phosphatidylinositol Phosphates; D010716:Phosphatidylinositols; D011506:Proteins; C060974:phosphatidylinositol 3,4,5-triphosphate; D010744:Phosphoric Monoester Hydrolases; D051059:PTEN Phosphohydrolase; C487757:Pten protein, mouse
Genes Immun. 2007 Jul;8(5):416-21
17538631
Cancer Res. 2004 May 1;64(9):3014-21
15126336
Br J Cancer. 2008 Nov 18;99(10):1557-63
19002177
Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9052-7
9256433
BMC Biochem. 2008 Oct 21;9 Suppl 1:S4
19007434
Cell. 1998 Oct 2;95(1):29-39
9778245
J Biol Chem. 1998 May 29;273(22):13375-8
9593664
Curr Biol. 1998 Oct 22;8(21):1195-8
9799739
J Biol Chem. 1998 Jun 26;273(26):16601-7
9632733
Mol Cell Biochem. 2002 Jul;236(1-2):75-81
12190124
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10182-7
10468583
Int J Gynecol Cancer. 2007 May-Jun;17(3):687-96
17504382
Cancer Res. 1998 Nov 15;58(22):5002-8
9823298
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15406-11
9860981
Cell Oncol. 2005;27(3):191-8
16037640
Genes Chromosomes Cancer. 2000 Oct;29(2):166-72
10959096
Dermatol Clin. 1995 Jan;13(1):27-31
7712647
Science. 1997 Mar 28;275(5308):1943-7
9072974
J Pathol. 2009 Apr;217(5):677-84
19097070
Int J Cancer. 2008 Feb 1;122(3):658-63
17935125
J Gastroenterol Hepatol. 2003 Jun;18(6):712-8
12753155
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4240-5
10200246
Clin Cancer Res. 2001 Jan;7(1):81-8
11205922
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13513-8
9811831
Oncogene. 2008 Sep 18;27(41):5497-510
18794884
Nat Genet. 1997 May;16(1):64-7
9140396
Biochim Biophys Acta. 2007 Oct;1772(10):1134-42
17681738
Cancer Sci. 2008 Feb;99(2):209-13
18201277
Genes Chromosomes Cancer. 2007 Jan;46(1):1-9
17044060
Cancer Sci. 2008 Apr;99(4):810-5
18377429
Mol Carcinog. 2000 Feb;27(2):110-6
10657903
Gynecol Oncol. 2000 Feb;76(2):193-9
10637069
Cancer Cell. 2005 Mar;7(3):263-73
15766664
J Surg Oncol. 2006 Mar 1;93(3):233-40
16482604
Nat Genet. 1998 Aug;19(4):348-55
9697695
Breast Cancer Res. 2005;7(6):R1186-98
16457699
Cell. 2007 Jan 12;128(1):129-39
17218260
Cell. 1999 Oct 29;99(3):323-34
10555148
Nat Rev Cancer. 2006 Mar;6(3):184-92
16453012
Virology. 2009 Jan 5;383(1):78-85
19007961
Mod Pathol. 2008 Nov;21(11):1345-56
18622384
Int J Gynecol Cancer. 2006 May-Jun;16(3):1254-60
16803514
J Biol Chem. 2001 Jan 12;276(2):993-8
11035045
Mol Cell Neurosci. 2001 Feb;17(2):385-97
11178875
Mol Med. 2005 Jan-Dec;11(1-12):59-63
16557333
Cytogenet Genome Res. 2007;118(2-4):130-7
18000363
Cancer Res. 2007 Sep 1;67(17):8229-39
17804737
Nat Med. 1999 Jun;5(6):707-10
10371512
Gynecol Oncol. 2004 Jun;93(3):621-7
15196854
Cell. 2007 Jul 13;130(1):51-62
17632056
Int J Oncol. 2001 Mar;18(3):493-7
11179477
Cell. 2000 Feb 18;100(4):387-90
10693755
Cancer Res. 1999 Jun 1;59(11):2551-6
10363971
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9418-23
9689095
Hepatology. 2003 Nov;38(5):1242-9
14578863
Gynecol Oncol. 2009 Mar;112(3):583-9
19110305
Rev Med Virol. 2009 Mar;19(2):97-113
19156753
Nat Genet. 1997 Apr;15(4):356-62
9090379
J Biol Chem. 2005 Jun 10;280(23):22523-9
15824124
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50
9560261
J Biol Chem. 2001 Aug 10;276(32):30461-6
11399756
J Biol Chem. 1997 May 9;272(19):12318-27
9139676
Cancer Res. 2004 Jul 15;64(14):4817-25
15256451
Cell. 1997 Feb 21;88(4):435-7
9038334
Int J Cancer. 2006 Apr 15;118(8):1877-83
16287065
J Clin Invest. 2008 Nov;118(11):3762-74
18830414
Curr Biol. 1998 Oct 22;8(21):1169-78
9799734
Cell Oncol. 2005;27(1):57-65
15750208